相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial
Andrey A. Ivashchenko et al.
CLINICAL INFECTIOUS DISEASES (2021)
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19
Florence Ader et al.
CLINICAL MICROBIOLOGY AND INFECTION (2021)
Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
Faryal Khamis et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
D. M. Weinreich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies
Silke Gastine et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
Masoud Solaymani-Dodaran et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Zarir F. Udwadia et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
Anil Gupta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen et al.
SCIENCE (2021)
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial
Li-An K. Brown et al.
TRIALS (2021)
Saliva is superior over nasopharyngeal swab for detecting SARS-CoV2 in COVID-19 patients
Getachew Tesfaye Beyene et al.
SCIENTIFIC REPORTS (2021)
Saliva is a reliable and accessible source for the detection of SARS-CoV-2
Luis A. Herrera et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5′-triphosphate exposure to support posology for SARS-CoV-2
Henry Pertinez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Validation of a combined ELISA to detect IgG, IgA and IgM antibody responses to SARS-CoV-2 in mild or moderate non-hospitalised patients
A. M. Cook et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2021)
Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial
Masaharu Shinkai et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
Usman Arshad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Peter W. Horby et al.
LANCET (2020)
Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity
Suzanne J. F. Kaptein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza
Yeming Wang et al.
EBIOMEDICINE (2020)
Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load
Antonio Goncalves et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2020)
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers
S. Y. Park et al.
JOURNAL OF HOSPITAL INFECTION (2019)
Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted
Thi Huyen Tram Nguyen et al.
PLOS NEGLECTED TROPICAL DISEASES (2017)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)